Regeneron Pharmaceuticals is a biotechnology company focused on the discovery, development, and commercialization of innovative medicines for serious diseases. Its core products include EYLEA, a treatment for eye diseases, and REGEN-COV, a COVID-19 therapy. The company operates primarily in the healthcare sector, with major revenue sources stemming from product sales and collaborations. Regeneron invests heavily in research and development to expand its portfolio and pipeline of therapies.
The investment profile of Regeneron Pharmaceuticals is more aligned with growth investors due to its focus on innovation and potential for future revenue increases. The company offers a modest dividend yield, appealing to those seeking some income, but its primary appeal lies in growth potential. The stock may be more suitable for medium to long-term investors who can tolerate volatility.
| Date | Before | After | Reason |
|---|---|---|---|
| 2026-10-09 | Hold | Buy | Strong fundamentals, but mixed momentum signals present uncertainty. |
| 2026-09-29 | Buy | Hold | Weak momentum and high risk; hold for now. |
| 2026-09-18 | Hold | Buy | Strong fundamentals and positive momentum support growth outlook. |
| 2026-09-12 | Buy | Hold | Strong fundamentals but recent negative momentum raises concerns. |
| 2026-08-02 | Hold | Buy | Strong momentum and solid fundamentals support growth potential. |
| 2026-07-21 | Sell | Hold | Weak fundamentals and negative momentum raise concerns. |
| 2026-07-12 | Hold | Sell | Weak fundamentals and negative momentum raise concerns. |
| 2026-07-04 | Sell | Hold | Weak fundamentals and negative momentum raise concerns. |
| 2026-06-03 | Hold | Sell | Weak momentum and fundamentals raise significant risk. |
| 2026-05-24 | Sell | Hold | Weak momentum and fundamentals raise significant risk. |
| 2026-05-16 | Hold | Sell | Weak fundamentals and negative momentum raise concerns. |
| 2026-05-08 | — | Hold | Weak fundamentals and negative momentum raise concerns. |
| 2026-05-03 | Buy | Hold | Компания демонстрирует снижение выручки и негативные тренды на коротких временных интервалах, однако имеет положительный долгосрочный потенциал с учетом роста за последние 120 дней. |
| 2026-02-06 | Hold | Buy | Компания показывает сильный рост за последние 120 дней, что свидетельствует о положительной динамике. Несмотря на недавние колебания, долгосрочные перспективы остаются многообещающими. |
| 2026-01-29 | Buy | Hold | Компания показывает сильный рост за последние 120 дней, но недавние колебания цен и отсутствие данных по EPS и выручке вызывают опасения. Рекомендуется удерживать акции до получения более ясной финансовой информации. |
| 2026-01-22 | Hold | Buy | Компания Regeneron демонстрирует сильный рост за последние 60 и 120 дней, что указывает на положительные перспективы. Несмотря на недавние колебания, долгосрочные тренды и потенциал роста делают её привлекательной для ин |
| Date | Analyst | Action | Target | Price Then |
|---|---|---|---|---|
| 2026-10-19 | Piper Sandler | Target Raised | 854 → 865 | 790.74 |
| 2026-10-14 | UBS | Update | — → 978 | 778.36 |
| 2026-10-08 | RBC Capital | Target Raised | 737 → 810 | 730.075 |
| 2026-10-08 | Raymond James | Update | — → 911 | 742.12 |
| 2026-10-07 | Truist Financial | Target Raised | 772 → 780 | 747.51 |
| 2026-10-07 | Morgan Stanley | Target Raised | 758 → 779 | 743.6 |
| 2026-10-01 | Jefferies | Target Raised | 870 → 930 | 741.16 |
| 2026-10-01 | BMO Capital | Update | — → 920 | 741.41 |
| 2026-10-01 | Argus Research | Update | — → 850 | 758.27 |
| 2026-09-10 | HSBC | Target Raised | 800 → 920 | 807.65 |
| 2026-08-17 | Leerink Partners | Target Raised | 641 → 824 | 803.48 |
| 2026-08-14 | Bernstein | Target Raised | — → 756 | 799.4583 |
| 2026-08-03 | Guggenheim | Target Raised | 1000 → 1030 | 763.51 |
| 2026-07-31 | RBC Capital | Target Raised | 696 → 737 | 739.5 |
| 2026-07-31 | Morgan Stanley | Target Raised | 730 → 758 | 738.82 |
| 2026-07-31 | Cantor Fitzgerald | Target Raised | 750 → 795 | 742.59 |
| 2026-07-31 | Robert W. Baird | Target Raised | 742 → 761 | 738.34 |
| 2026-07-31 | Wells Fargo | Target Raised | 700 → 750 | 738.34 |
| 2026-07-21 | Guggenheim | Target Raised | 995 → 1000 | 675.72 |
| 2026-07-09 | Piper Sandler | Target Lowered | 855 → 854 | 662.88 |
| 2026-07-08 | Morgan Stanley | Target Lowered | 788 → 730 | 676.23 |
| 2026-07-07 | Truist Financial | Target Lowered | 778 → 769 | 670.537 |
| 2026-07-06 | HSBC | Target Lowered | 990 → 800 | 642.995 |
| 2026-07-06 | Cantor Fitzgerald | Target Lowered | — → 750 | 654.27 |
| 2026-05-19 | Canaccord Genuity | Target Lowered | 1057 → 875 | 629.68 |
| 2026-05-18 | Wolfe Research | Target Lowered | 900 → 860 | 629.36 |
| 2026-05-18 | Evercore ISI | Target Lowered | 875 → 825 | 619.84 |
| 2026-05-18 | RBC Capital | Target Lowered | 762 → 707 | 619.6201 |
| 2026-05-18 | Truist Financial | Target Lowered | 796 → 778 | 619.95 |
| 2026-05-18 | BMO Capital | Target Lowered | 900 → 730 | 698.25 |
| 2026-05-18 | Piper Sandler | Target Lowered | 875 → 855 | 698.25 |
| 2026-05-18 | Leerink Partners | Update | — → 641 | 698.25 |
| 2026-05-01 | Guggenheim | Target Raised | 975 → 995 | 707.06 |
| 2026-04-30 | Morgan Stanley | Target Lowered | 796 → 788 | 703.1789 |
